Skip to main content

Table 1 Demographic/biopsy data of UCSD patient cohort with evaluable TMBs for multiple biopsies and clinical data

From: Intra-patient stability of tumor mutational burden from tissue biopsies at different time points in advanced cancers

Factor Item Value [95% CI]
  Average time between biopsies (days) 722 [621–821]
Average TMB difference (mutations/Mb) 0.583 [− 0.900–2.064]
Age at first biopsy (years) 57.36 [55.22–59.50]
Gender Men 106 (52.48%)
Women 96 (47.52%)
Diagnoses Colorectal adenocarcinoma 29 (14.36%)
Lung adenocarcinoma 20 (9.901%)
Breast invasive ductal adenocarcinoma 10 (4.950%)
Metastatic (any primary) 99 (49.00%)
Biopsy sites First biopsy Last biopsy
Lung 22 (10.89%) Liver 33 (16.34%)
Colon 19 (9.406%) Lung 20 (9.901%)
Soft Tissue 16 (7.921%) Lymph Node 16 (7.921%)
Bone Marrow 11 (5.446%) Bone Marrow 14 (6.931%)
Liver 11 (5.446%) Colon 12 (5.941%)
Others 123 (60.89%) Others 107 (52.97%)
Immunotherapy (checkpoint) Number receiving immunotherapy between biopsies 55 (27.23%)
Number NOT receiving immunotherapy 147 (72.77%)
TMB measured High at first biopsy (≥ 20 mutations/Mb) 10 (4.950%)
Intermediate at first biopsy (5 < TMB ≤ 19 mutations/Mb) 49 (24.26%)
Low at first biopsy (≤ 5 mutations/Mb) 143 (70.79%)
High at second biopsy (≥ 20 mutations/Mb) 13 (6.436%)
Intermediate at second biopsy (5 < TMB ≤ 19 mutations/Mb) 50 (24.75%)
Low at second biopsy (≤ 5 mutations/Mb) 139 (68.81%)
  1. Patients in the UCSD cohort (N = 202) tend to be older and are roughly evenly distributed between men and women. Almost half (49%) of the patients have metastatic cancer. 55 of them (27.23%) received immunotherapy between their first and last biopsies, on average 722 days apart
  2. Data derived from medical record; if tobacco or alcohol exposure not known, then patients not counted